Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 24, 2025, titled "Dr. Reddy s receives European Commission approval for AVT03 (denosumab), a proposed Biosimilar of Prolia® and Xgeva®".
Press Release Nov 24 2025
Filed with NSE · · 3 pages · English
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings CallRelease
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
- Press Release Oct 13 2025
- Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
- Press Release Sep 16 2025
Later from Dr. Reddy's Laboratories
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
- Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
- Dr. Reddy's Laboratories Ltd. Press Release Dec 12 2025
- Press Release Jan 08 2026
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories